Clinical Trial Update: Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating daily versus weekly dosing of cladribine for hairy cell leukemia has completed, reporting results on dosing schedules.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hairy Cell Leukemia

Drugs mentioned

• Leustatin (cladribine)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Leukemia | Phase 3 | Status: COMPLETED